Gene therapy vector for improving eye diseases and application thereof
Through AAV2/8-mediated PDE6B gene therapy, recombinant adeno-associated viral vectors are used to replace mutant genes in retinal cells, solving the problem of lack of effective treatment methods in retinal pigmentation treatment, and achieving efficient, safe and long-term therapeutic effects .
Patent Information
- Application Number
- CN202410897760.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-05
- Publication Date
- 2024-11-15
AI Technical Summary
The existing treatment methods for retinal pigmentation lack effective fundamental treatment methods, especially for diseases caused by PDE6B gene mutations. The treatment effect is limited, frequent intervention is required and safety risks are present.
AAV2/8-mediated PDE6B gene therapy is used to replace the mutant genes in patients' bodies by introducing normal PDE6B genes, and gene replacement therapy is used to ensure the accuracy and safety of the treatment.
Accurate repair of PDE6B gene deletion or defects has been achieved, which significantly improves treatment efficiency, reduces the risk of side effects, provides long-term therapeutic effects, and improves the safety and reliability of treatment.
Smart Images

Figure CN118956964A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedical engineering and gene therapy, and specifically relates to a gene therapy vector for improving eye diseases and its application, that is, the gene therapy DNA vector containing the therapeutic gene can be used to deliver it to the cells of humans and animals experiencing reduced or insufficient expression of the gene, thereby ensuring the desired therapeutic effect. Background Art
[0002] Retinitis Pigmentosa (RP) is a group of inherited retinal diseases, usually manifested as gradually progressive vision loss, night blindness, reduced visual field and gradual damage to rod cells. From a genetic perspective, there are four main ways of inheritance of RP: autosomal dominant, autosomal recessive, X-linked recessive and sporadic. Autosomal recessive RP accounts for about 5%-20%, of which the disease caused by mutations in the Pde6b gene (encoding the rod cell phosphodiesterase type 6 β subunit) accounts for 4%-5% of autosomal recessive RP. Pde6b gene mutations lead to serious biological effects in rod cells. Specifically, when the Pde6b gene mutates, the phosphodiesterase in the rod cells loses its normal function and cannot hydrolyze cyclic guanosine monophosphate (cGMP) in the cell. This leads to the accumulation of cGMP in the cell and keeps the cGMP-gated cation channel in an open state. This situation leads to a large influx of calcium ions, which triggers damage and death of rod cells, ultimately leading to retinitis pigmentosa.
[0003] In the first stage of retinitis pigmentosa, rod photoreceptors show mild functional defects, the retinal structure remains largely intact, and the photoreceptor outer segments are shortened. At this stage, neuroprotective treatment strategies may extend the life of rod photoreceptors, while gene replacement therapy and genome editing can slow down or stop the degeneration process. Therefore, gene therapy strategies in the first stage are more helpful for the treatment of patients.
[0004] The second stage of retinitis pigmentosa is characterized by further shortening and loss of photoreceptor outer segments, a decrease in the number of rods and cellular connectivity with the outer plexiform layer, and activation of glial cells. In this stage, in addition to paying attention to neuroprotection, gene therapy can rescue affected photoreceptors and may reverse some functional defects by promoting outer segment repair.
[0005] The third stage of retinitis pigmentosa is the late stage of photoreceptor loss, when cones also die, followed by structural remodeling of the plexiform layer, more active glial cell reactions, and more obvious degeneration of second-order neurons. In addition, photoreceptor degeneration triggers overactive discharges of retinal ganglion cells, masking the light responses caused by surviving photoreceptors. At this stage, the degree of degeneration is more intense, and treatment needs to consider how to induce light responsiveness. In addition, the intervention of optogenetics, cell therapy, or electronic prosthesis is also needed. For example, combining optogenetics, cell therapy, or retinal implants with drugs that inhibit ganglion cell overactivity (such as meclofenac or retinoic acid receptor inhibitors) can further improve the quality of restored visual responses. Cell therapy may also be applicable to the third stage of degeneration, that is, transplanted photoreceptors have the potential to establish meaningful connections with neurons in the retina.
[0006] Stage IV of retinitis pigmentosa is characterized by near-complete or total loss of photoreceptor cells, translocation of neuronal cells within the retina, remodeling of deep synapses, and possible migration of the RPE into the rod layer. In addition, gliosis, hyperactivity, and scar tissue formation around neurons in different layers may impede afferent connections of transplanted cells using subretinal spatial locations. Optogenetic therapy and retinal implants that deliver electrical stimulation to the remaining inner nuclear layer cells and ganglion cells may be appropriate treatment strategies for stage IV. Retinal disorganization and gliosis may be too advanced for cell-based therapies to result in integration of photoreceptors and formation of meaningful synaptic connections.
[0007] Although there are some treatments for retinitis pigmentosa, there is still a lack of effective treatments, especially for RP caused by PDE6B gene mutations. The main defects and deficiencies include:
[0008] 1. Lack of fundamental treatment methods: Existing treatments for retinitis pigmentosa are mainly aimed at alleviating disease symptoms, but fail to effectively restore the function of damaged photoreceptors, and thus cannot truly reverse the progressive degeneration of RP.
[0009] 2. Limited treatment effect: Although traditional drug treatment can help patients maintain their vision to a certain extent, it has not been able to significantly improve patients' visual function.
[0010] 3. Sustainability issues: Some treatments require frequent intervention or treatment, which brings inconvenience to patients. Moreover, the treatment effect gradually weakens over time and cannot provide long-term and sustained effects.
[0011] 4. Safety issues: Some existing treatments may be accompanied by potential safety risks, and some gene therapy methods may induce unnecessary changes in gene expression, such as immune responses or inappropriate gene expression. Summary of the invention
[0012] In order to solve the fundamental technical problems in the treatment of retinitis pigmentosa, the present invention aims to provide a method for treating autosomal recessive retinitis pigmentosa caused by Pde6b mutation by PDE6B gene therapy based on adeno-associated virus 2 / 8 (AAV2 / 8) vector. Specifically, AAV2 / 8 is used as a vector to deliver the normal Pde6b / PDE6B gene into the Pde6b rd10 The drug is then inserted into the retinal cells of mice to replace the disease-causing recessive gene, thereby achieving a safe, efficient and long-lasting therapeutic effect.
[0013] Based on the above purpose, a recombinant adeno-associated virus vector expressing human PDE6B gene is characterized in that it contains an expression cassette, which includes a promoter and human PDE6B gene, and the promoter is a pan-promoter EF-1α or CMV promoter.
[0014] The expression cassette includes a regulatory sequence downstream, and the regulatory sequence includes a mutated woodchuck stomatitis virus post-transcriptional regulatory element WPRE.
[0015] The polyadenylation sequence is included downstream of the regulatory sequence, and the polyadenylation sequence is included in SV40 polyA.
[0016] The recombinant adeno-associated virus vector comprises the following elements in sequence: a 5' terminal inverted repeat sequence, an expression cassette, a regulatory sequence, a polyadenylation sequence, and a 3' terminal inverted repeat sequence.
[0017] The serotypes of the adeno-associated virus vector include AAV2 / 8.
[0018] Plasmid combination, including recombinant adeno-associated virus vector and helper plasmid for virus packaging.
[0019] The helper plasmid for virus packaging includes Rep-Cap plasmid.
[0020] Host HEK293T cells, transfected or transformed with the recombinant vector;
[0021] Or transfect or transform the plasmid combination.
[0022] The host includes but is not limited to prokaryotes or animal cells; the prokaryotes include but are not limited to Escherichia coli; the animal cells include but are not limited to one or more of CHO cells, BHK cells, Sp2 / 0, HEK-293, HEK293T, Hep G2, HELA, CHO-K1, COS-1, COS-7, NIH3T3, A204, A549, D-407, CHO, HCS-2, HT-29, U87, Sf9 or FD-CHOS.
[0023] Virus particles were prepared by:
[0024] The recombinant adeno-associated virus vector;
[0025] The plasmid combination;
[0026] The host.
[0027] The following use in preparing a vaccine and / or a drug for preventing, improving and / or treating retinitis pigmentosa;
[0028] (I), the recombinant adeno-associated virus vector;
[0029] or (II), the plasmid combination described;
[0030] Or (III), the viral particles.
[0031] Compared with the prior art, the main advantages and beneficial effects of the present invention are mainly reflected in:
[0032] In terms of specificity, PDE6B gene replacement therapy has a significant advantage over traditional gene therapy. The core advantage of this treatment method is that it can directly and precisely repair the deletion or defect of the PDE6B gene in the patient's body. By introducing the normal PDE6B gene sequence, this replacement therapy quickly and accurately restores the function of the affected gene and helps to resolve the physiological abnormalities associated with its defect. In traditional gene therapy, mediated gene expression methods may be used, such as using viral vectors to introduce normal genes into the patient. However, this method may not achieve the same accuracy as direct replacement of the PDE6B gene. PDE6B gene replacement therapy ensures a high degree of targeting of the treatment and minimizes non-specific effects by directly replacing the mutant gene sequence in the patient.
[0033] By introducing a healthy PDE6B gene, the therapy repairs the genetic defect in a precise and targeted way, avoiding unintended effects on other parts of the patient's genome. This reduces the risk of possible adverse reactions caused by the treatment compared to the broad genetic interventions that may be involved in traditional gene therapies. Because PDE6B gene replacement therapy focuses on addressing problems with a specific gene, patients are more likely to experience fewer or milder side effects during treatment. This advantage is critical to improving the overall safety and reliability of the treatment, especially considering that side effects may negatively affect the patient's quality of life and efficacy.
[0034] In terms of treatment efficiency, PDE6B gene replacement therapy shows better characteristics than traditional gene therapy. Its excellence lies in providing higher treatment efficiency by directly repairing the gene defects in the patient's body without relying on auxiliary treatment methods. This direct repair mechanism makes the treatment process faster and more precise, thereby producing significant disease relief effects in a relatively short period of time. Compared with traditional gene therapy, the latter may need to be supplemented with other treatment methods, such as drugs or substance mediation, to achieve disease relief. These auxiliary methods may introduce additional complexity and add unnecessary steps in the treatment process.
[0035] No exogenous substances are introduced, which makes it safer. Gene replacement therapy replaces defective genes by introducing healthy genes, and usually does not involve direct modification of the genome, thus reducing the risk of unexpected mutations. In traditional gene therapy, the introduction of viral vectors may trigger immune responses or other side effects. PDE6B gene replacement therapy avoids the use of exogenous vectors, reduces these potential treatment risks, and makes the treatment safer. Random insertion can be avoided. In traditional gene therapy, viral vectors may be inserted into the cell genome in a random manner, leading to unexpected gene mutations. In comparison, PDE6B gene replacement therapy has lower immunogenicity. Since it does not involve exogenous viral vectors, PDE6B gene replacement therapy has more advantages in immunogenicity. This helps to reduce the risk of immune response during treatment and increase the controllability of treatment.
[0036] Long-lasting therapeutic effect, long-term expression after gene introduction. PDE6B gene replacement therapy achieves long-term expression of normal protein by directly replacing the PDE6B gene in the patient's cells. The introduced healthy gene can be continuously expressed, providing long-term therapeutic effects, especially when gene expression in the body is relatively stable. Gene replacement therapy can achieve long-term stable expression in the patient's body and continue to exert a therapeutic effect by introducing a healthy gene once. This is particularly important for the treatment of chronic genetic diseases, which can significantly improve the patient's quality of life and reduce the need for frequent treatment.
[0037] Reduced treatment risk and good biocompatibility. Mainly reflected in: no exogenous vectors. In traditional gene therapy, viral vectors are often used to deliver therapeutic genes into cells. The introduction of such exogenous vectors may lead to immune responses, cytotoxicity and potential safety issues. In comparison, PDE6B gene replacement therapy avoids the use of exogenous vectors, reduces the risks of immunogenicity and cytotoxicity, avoids virus-related maladaptive reactions, and minimizes unintentional intervention in other genes by directly replacing the defects of the PDE6B gene, thereby reducing potential side effects during treatment.
[0038] The operation is simple. The process of gene replacement therapy is usually relatively straightforward, that is, the healthy gene is introduced through viral vectors or other means, without the need for complex editing tools and precise editing steps. In contrast, gene editing technology requires highly precise tools and techniques to identify and cut the target gene region, and then repair or replace it. Gene replacement therapy can introduce healthy genes directly into patient cells through vectors such as adeno-associated virus (AAV). The operation is relatively simple and highly controllable.
[0039] Unlike traditional gene therapy techniques, the AAV2 / 8-mediated method can more accurately locate and replace damaged genes, reducing the risk of off-target effects. Studies over the years have shown that AAV2 / 8 has relatively high safety and tolerability in clinical applications, and can better meet treatment needs. The use of WPRE's powerful viral post-transcriptional regulatory elements can significantly improve gene expression efficiency. It participates in RNA poly A modification, RNA nuclear export and translation to regulate the expression of target genes. Using the SV40 PolyA sequence, it has a transcription termination effect and a DNA sequence that adds a PolyA tail to the transcribed mRNA, which helps protect the mRNA from rapid degradation. The SV40 polyA signal sequence can be used in combination with a variety of promoters and enhancers, and can play a role in different retinal cell types (such as rods, cones, retinal pigment epithelial cells, etc.), and has a wide range of applicability.
[0040] In this treatment, we chose the EF1α promoter instead of the CMV promoter. The CMV promoter is derived from cytomegalovirus and tends to be highly expressed in tumor cell lines, while the EF1α promoter is derived from human genes and is therefore more easily accepted in retinal tissue, reducing the possibility of immune-related problems. In addition, the stability and wide applicability of the EF1α promoter ensure that long-lasting and reliable gene expression can be achieved in different types of cells. Compared with the CMV promoter, the use of the EF1α promoter has higher effectiveness and stability in retinal treatment, thereby providing more reliable support for the effectiveness and safety of gene therapy, achieving simultaneous treatment of cones and rods, and improving the thickness of the photoreceptor cell layer. BRIEF DESCRIPTION OF THE DRAWINGS
[0041] Figure 1 The structure of the rAAV-CMV-Pde6b / rAAV-EF1α-Pde6b / rAAV-EF1α-hPDE6B vector genome;
[0042] Figure 2 Implementation method of pCMV-Pde6b-WPREm cis vector plasmid map;
[0043] Figure 3 This is an embodiment of the pEF1α-Pde6b-WPREm cis vector plasmid map;
[0044] Figure 4 Implementation method of the pEF1α-hPED6B-WPREm cis vector plasmid map;
[0045] Figure 5 This is the experimental flow chart;
[0046] Figure 6 Results of the retinal GFP examination for the injection of 18M;
[0047] Figure 7 Results 2 of the examination of GFP in the retina for the injection of 18M;
[0048] Figure 8 Gene replacement therapy protects Pde6b in P18M rd10 Mouse photoreceptors, the ordinate represents retinal thickness;
[0049] Fig. 9 ERG is used to detect cone and rod function;
[0050] Fig.10 Pde6b after gene therapy rd10 The mice had significant optokinetic responses, and OMR values represented the quantitative measure of optokinetic responses. DETAILED DESCRIPTION
[0051] Unless otherwise specified, the experimental methods used in the following examples are commonly used laboratory methods.
[0052] It should be understood by those skilled in the art that the discussion of any of the following embodiments is merely illustrative and is not intended to imply that the scope of the present invention (including the claims) is limited to these examples; within the context of the present invention, the technical features in the above embodiments or in different embodiments may be combined, the steps may be implemented in any order, and there are many other variations of the different aspects of the present invention as described above, which are not provided in detail for the sake of simplicity.
[0053] The present invention is intended to cover all such substitutions, modifications and variations that fall within the broad scope of the appended claims. Therefore, any omissions, modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the scope of protection of the present invention.
[0054] Example 1: Nucleic acid vector of the present invention
[0055] In this exemplary embodiment, the pAAV-CMV-Puro / pAAV-EF1α-Puro vector is a hybrid AAV-based vector carrying the cDNA of the mPde6b / hPDE6B subunit of mouse / human rod cGMP phosphodiesterase. The mPde6b / hPDE6B cDNA is expressed under the control of a pan-promoter (CMV or EF-1α) and enhanced using a mutated woodchuck stomatitis virus post-transcriptional regulatory element (WPRE) sequence. The expression cassette is flanked by AAV serotype 2 / 8 terminal inverted repeats (ITRs) and the recombinant genome is packaged in an AAV serotype 2 / 8 capsid. The expression cassette contains the following elements:
[0056] CMV promoter: 0.5 Kb
[0057] EF-1α promoter: 0.2 Kb
[0058] cDNA of the Pde6b subunit of mouse rod cGMP phosphodiesterase: 2.57 Kb
[0059] cDNA of the PDE6B subunit of human rod photoreceptor cGMP phosphodiesterase: 2.57 Kb
[0060] Woodchuck stomatitis virus posttranscriptional regulatory element (WPRE) with a point mutation in the ATG codon of the WHV-X open reading frame: 0.54 Kb
[0061] Simulates the polyadenylation signal of virus 40 (SV40): 0.1 Kb
[0062] AAV serotype 2 / 8 inverted terminal repeats (ITRs): 0.13Kb
[0063] The structure of the pAAV-CMV-Pde6b / pAAV-EF1α-Pde6b / pAAV-EF1α-hPDE6B vector genome is depicted in Figure 1 Including the 5′ terminal inverted repeat sequence of AAV2 / 8, the promoter EF-1α or CMV, the mouse or human PDE6B gene, the regulatory sequence WPRE, the polyadenylation sequence SV40 polyA, and the 3′ terminal inverted repeat sequence of AAV2 / 8.
[0064] Example 2: Plasmid construction
[0065] This embodiment involves constructing a plasmid to express a specific protein in a cell. The construction of the plasmid involves multiple steps, as described below.
[0066] 1. RNA was extracted from C57 mouse retina and human 293T cells to obtain cDNA, and the mouse Pde6b and human PDE6B sequences were amplified by PCR. The amplification system is shown in Table 1, and the amplification procedure is shown in Table 2. The mouse Pde6b and human PDE6B sequences are from the NCBI database, and the sequence numbers are: NM_008806.2, NM_000283. The primer sequences are as follows:
[0067] Mouse forward primer: atatacgtctcaatgagcctcagtgaggaacaggtacgc;
[0068] Mouse reverse primer: atatacgtctcattataggatacagcaggtcgaggacttggg;
[0069] Human forward primer: atatacgtctcaatgagcctcagtgaggagca;
[0070] Human reverse primer: atatacgtctcatcacaggatacagcaggttg;
[0071] Table 1 Amplification system
[0072] Components Dosage stencil 500ng Forward Primer / Reverse Primer 4 / 4μl 2×Hieff Canace PCR Master Mix 50μl <![CDATA[H2O]]> Make up to 100 μl
[0073] Table 2 Amplification procedures
[0074] step temperature time Number of cycles 1 98℃ 3:00 / 2 98℃ 0:10 / 3 60℃ 0:20 / 4 72℃ 1:00 / 5 72℃ 5:00 34 6 12℃ hold /
[0075] 2. The amplified fragments were digested by enzymes respectively. The enzyme digestion system is shown in Table 3.
[0076] Table 3 Enzyme digestion system
[0077] Components Dosage template 3000ng BbI 1.5μl 10×green buffer 5μl <![CDATA[H2O]]> Make up to 50ul
[0078] 3. The plasmid pAAV-EF1α-Puro / pAAV-CMV-Puro vector was digested with enzymes. The enzyme digestion system is shown in Table 4.
[0079] Table 4 Enzyme digestion system
[0080] Components Dosage template 3000ng Xgf 2μl HindIII 2μl 10×green buffer 5μl <![CDATA[H2O]]> Make up to 50ul
[0081] 4. Mouse Pde6b and human PDE6B sequences were inserted into plasmid pAAV-CMV-Puro / pAAV-EF1α-Puro by T4 ligase to construct Pde6b / PDE6B overexpression plasmid pAAV-CMV-Pde6b / pAAV-EF1α-Pde6b / pAAV-EF1α-hPDE6B. Plasmids pCap and pRep were used for AAV adeno-associated virus packaging, such as Figure 2-Figure 3 shown.
[0082] Example 3: Preparation of AAV virus
[0083] This step uses the characteristics of adenovirus that can efficiently infect eukaryotic cells without integrating into the cell genome. The AAV vector of the target gene to be expressed is packaged into the adenovirus, and then the plasmid is transfected into the mouse retinal photoreceptors. The specific operation of this process is as follows:
[0084] 1. Cell transfection
[0085] ① Prepare cells: One day before transfection, subculture HEK293T cells. After removing the cell supernatant, digest the cells with trypsin solution and add complete culture medium to stop. Use a pipette to blow the cell suspension until it is uniform. After counting the cells, prepare the cell suspension to the required concentration and transfer the cells to a 15 cm cell culture dish so that the cell density reaches 80% during transfection.
[0086] ②Prepare transfection mixture: 2h before transfection, replace all the culture medium with DMEM+10% FBS culture medium without double antibody, and wait until the cell state is stable. Prepare two 1.5ml sterile EP tubes, add an appropriate amount of plasmid to be transfected to tube A and mix it evenly with 500μl serum-free culture medium, add an appropriate amount of transfection reagent PEI to tube B and mix it evenly with 500μl serum-free culture medium, vortex and mix evenly, mix the two tubes of solution evenly, and get the transfection mixture at this time. Let it stand at room temperature for 30min, then gently add the transfection mixture to the transfected cell dish, and shake it gently from side to side to make it uniform.
[0087] ③ Change the medium after transfection: Add the prepared transfection mixture to the culture dish, which is transfection 0 hours, and continue to culture the cells in the CO2 incubator. If the virus is packaged with pAAV-EF1α-GFP as the core plasmid, observe whether GFP (green fluorescent protein) is expressed under a fluorescence microscope 12 hours after transfection. Discard the culture medium 24 hours after transfection, replace with new DMEM+2% FBS+1% double antibody basal medium, place in a cell culture incubator and continue to culture until 72 hours after transfection for subsequent experiments.
[0088] 2. Virus collection
[0089] Precool the centrifuge to 4°C in advance, collect all the cell culture medium of the cells that have been transfected for about 72 hours into a 50ml centrifuge tube, then scrape off all the transfected cells with a cell scraper, transfer the cells to the same centrifuge tube where the culture medium has just been collected with a pipette, seal it, and centrifuge it at 4°C at 3000r for 30min. After centrifugation, remove the supernatant and add Lysis buffer (5M NaCl, 2M Tris-HCl, pH8.0) to resuspend the cells.
[0090] 3. Isolation and purification of adeno-associated virus by iodixanol density gradient high-speed centrifugation: Rapidly freeze the cells in a dry ice / ethanol ice bath and rapidly thaw them in a 55°C water bath, repeat three times to lyse the cells; Digest the residual cell debris with Benzonase at 37°C, centrifuge and transfer the supernatant into the prepared iodixanol density gradient system with concentrations of 17%, 25%, 40% and 60% from top to bottom, and separate and purify the virus by ultracentrifugation.
[0091] 4. Virus concentration: Common methods for AAV virus concentration include ultrafiltration, centrifugal concentration or dialysis. Separate the virus-containing fraction from the centrifuged product, transfer it to the Amicon Ultra-15 Filter Unit, add sterile PBS, remove iodixanol by centrifugation and concentrate the virus solution to 200 μl.
[0092] 5. Real-time quantitative PCR to determine virus titer: Digest the virus capsid with 2M NaOH solution to release the viral genome, and use Real-time qPCR to determine the virus titer. If the titer is 2.0×10 13 -5.0×10 13 VG / mL, store the virus in a -80℃ refrigerator until use.
[0093] Example 4: Subretinal injection
[0094] Ethical Statement of Experimental Animals: The use of all experimental animals in this project was in accordance with the Animal Use Statement of the Association for Research in Vision and Ophthalmology. C57BL / 6J mice were purchased from Alpha Biotechnology Co., Ltd., and rd10 mice were purchased from Jackson Laboratory. rd10 mice are a mouse model carrying a spontaneous missense point mutation of the Pde6b gene, specifically the mutation of c.1678C>T, p.R560C. This mutation is associated with retinitis pigmentosa. The experimental mice lived in an environment with a room temperature of 22-25°C, a relative humidity of 40%-70%, a 12h light cycle, and clean water and food. All animal experimental equipment and materials have been approved and evaluated by the Animal Ethics Committee of Wuhan University of Science and Technology, and the treatment of mice during the experiment complies with animal ethics standards.
[0095] Pde6b born P14 rd10 After the mice were anesthetized, subretinal injections were performed under a surgical microscope. A sterile 30-gauge beveled needle was used to make an incision through the cornea on the nasal side. Subretinal injections were performed using a microinjector with a 32-gauge blunt-end needle, which was passed through the retina to the injection site while avoiding the lens. Each eye was injected with 0.7 μl of AAVs (approximately 10 11 VG / mL), 0.1% green buffer was added to the AAV mixture to facilitate observation during injection. Histological analysis, electroretinogram and optokinetic response test can examine the single eye of the mouse, so in Pde6b rd10 One eye of the mice was injected with pAAV-EF1α-GFP as a control group, denoted as the Ctrl group, and the other eye was injected with a double virus mixed with pAAV-EF1α-GFP and pAAV-CMV-Pde6b / pAAV-EF1α-Pde6b / pAAV-EF1α-hPDE6B for gene replacement therapy, denoted as the experimental group GR group. Figure 5 As shown, after the injection, apply an appropriate amount of erythromycin ointment to the wound site; put the mice on a heat blanket, and put them back into the cage and raise them normally for 18 months after they are fully awake.
[0096] like Figure 6 As shown, after injection of 18M, the GFP expression in the retina was examined and it was found that the Pde6b gene in the treated group was expressed by EF1α. GR / Human PDE6B GR The results showed that the mice stably expressed GFP after treatment. The expression of GFP as a control proved the effectiveness and durability of our subretinal injection treatment, and the treatment-related viral vector was successfully expressed in mice. Figure 6 The CMV promoter-expressing treatment group on the left side has a dark area, and the expression of GFP is relatively weak.
[0097] Example 5: Immunohistochemistry and imaging
[0098] This embodiment relates to methods of immunohistochemistry and imaging, as described below.
[0099] 1. Anesthesia and fixation of mice: After anesthetizing the normally raised 18-month-old mice of Example 4, they were perfused and fixed with 4% paraformaldehyde, and then the eyeballs were removed. The retina was carefully separated with forceps and placed in a solution containing 30% sucrose and OCT.
[0100] 2. Embedding and sectioning: The fixed retina was cut into 20 μm thick frozen sections in a cryostat (Leica CM1950). The sections can be prepared using steps such as dehydration, embedding and cutting.
[0101] 3. Antibody treatment and staining: The sections were washed in PBS and then incubated in blocking buffer in PBS containing 5% normal donkey serum (Jackson ImmunoResearch), 0.1% Triton X-100 and 0.1% NaN3 for 1 hour at room temperature. After overnight incubation with the primary antibody at 4°C, the sections were washed three times with PBS and then incubated with the secondary antibody for 2 hours in a wet dark box. The nuclei were stained with DAPI (Sigma-Aldrich) and then the sections were mounted with FluoromountG (SouthernBiotech).
[0102] 4. Immunofluorescence imaging: Confocal images were acquired using an Olympus FV3000 microscope. Ensure that all images were acquired under non-saturating conditions and that images to be compared were acquired using the same settings.
[0103] 5. Quantitative analysis of fluorescence intensity: Use ImageJ to quantitatively analyze the fluorescence intensity of each region of interest in the image. Use ImageJ's Analyze-Measure tool to calculate the average fluorescence intensity, and use Prism8 (GraphPad) for statistical analysis.
[0104] Figure 7 a and Figure 7 b shows that the GFP expression in the retina was examined after injection of 18M, and it was found that Pde6b GR -CMV / Pde6b GR / hPDE6B GR The results showed that after treatment, all mice had stable expression of GFP, and the location of high GFP expression was accompanied by thickening of the outer nuclear layer of the retina, which also indicated the effective effect of rescuing tissue degeneration.
[0105] Figure 8 Showing that gene replacement therapy protects Pde6b at P18M rd10 Mouse photoreceptor, Pde6b rd10 The retinal thickness of blind and degenerative mice was within 5 μm, and Pde6b GR-CMV / Pde6b GR / hPDE6B GR The results showed that after three treatments, the retinal thickness of mice was significantly improved. GR-CMV The therapeutic effect is relatively weak.
[0106] Example 6: ERG (Electroretinogram)
[0107] This embodiment involves electrophysiological recordings in mice, as described below.
[0108] 1. Anesthesia and pupil dilation of mice: 1% Tropicamide and 1% Atropine were used to anesthetize and dilate the pupils of the normally raised 18-month-old mice in Example 4.
[0109] 2. ERG recording: ERGs were recorded from the corneal surface using a pair of platinum ring electrodes (RetiMINER-C, IRC), while a ground electrode was placed at the tail and a reference electrode was placed at the forehead between the eyes. Genteal gel (Alcon) was dropped on the cornea to keep it moist. For dark-adapted ERGs, mice were dark-adapted at night (Scotopic) and stimulated with gradually increasing light intensities (-3.6, -2.6, -1.6, -0.6, 0.4, 1.4, and 2.15 log·cds / m 2 For light-adapted ERG, mice were light-adapted for 10 min (Scotopic) and simultaneously presented with a white background light (30 cds / m 2 ) were stimulated at (-0.6, 0, 0.6, 1, 1.4 and 2.15 log·cds / m 2 ). The bandpass filter was set between 0.3 and 300 Hz, and the responses were averaged from 10 single flashes under different stimulation conditions. All data were analyzed by RetiMINER 4.0.
[0110] like Fig. 9 As shown, ERG detects cone and rod function. The a-wave and b-wave values reflect the cone and rod function. After treatment, Pde6b GR / hPDE6B GR The amplitudes of a-wave and b-wave of mice were significantly improved, and the cone and rod functions were improved. GR-CMV The effect of the treatment group was relatively poor.
[0111] Example 7: Eye Tracker
[0112] This embodiment involves the assessment of visuomotor reflexes using an automated head tracking system, as described below.
[0113] 1. Experimental setup: The mice were placed on a central elevated platform, and vertical sinusoidal grating stimulation was projected on the surrounding LCD monitors. A virtual cylinder was randomly rotated in the horizontal direction (12° / s) to form a visual stimulation environment.
[0114] 2. Visual stimulation parameters: Stimuli can be either vertically rotated or counterclockwise, and are randomly generated. Stimuli can be presented at maximum contrast (100%) with six different spatial frequencies (0.02, 0.1, 0.15, 0.2, 0.3, and 0.4 cycles / °), or at optimal spatial frequency (0.2 cycles / °) with six different contrasts (100, 50, 25, 12.5, 10, and 5%). Each spatial frequency or contrast level of stimulation lasted 50 seconds and was presented in a random order and direction.
[0115] 3. Data recording and analysis: The head movement caused by the stimulus is recorded using a camera placed above the animal, and the position of the mouse head is automatically tracked by the OptoTrack XR-OT101 system (OptoTrack version 4, XINRUN) algorithm. In this way, the angle of the head relative to the moving grating stimulus can be automatically calculated, so that the measurement results can be obtained objectively, excluding subjective intervention from human observers. The visual motion response can be determined and quantified by calculating the ratio of the total time (converted to the total number of frames in the algorithm) that the animal's head moves in the stimulus direction and the opposite direction (Tcorrect / Tincorrect, referred to as OMR).
[0116] like Fig.10 Shown is Pde6b after gene therapy rd10 The mice showed significant optokinetic responses, and the visual acuity of the entire visual pathway was improved regardless of whether the gratings were tested at different spatial frequencies or at different grating contrasts. GR / hPDE6B GR group had better optomotor response, while Pde6b GR-CMV The treatment effect of group was poor.
[0117] The changes in retinal structure after treatment were analyzed histologically, and the changes in the number of rods, cones and other neurons in the mouse retina were evaluated by immunofluorescence staining, confocal imaging and related data analysis to verify the durability and structural integrity of the treatment. Secondly, the electroretinogram response experiment further confirmed that the visual conduction function of rd10 mice was maintained after gene therapy. Finally, the eye tracker behavioral experimental system was used to intuitively detect the visual reaction time, visual sensitivity, visual positioning, visual memory and eye tracking of the mice after treatment to evaluate the degree of improvement in the visual function of the mice.
[0118] The above nucleotide and amino acid sequences of the present invention are numbered as follows in the sequence listing.
[0119] Pde6b nucleotide sequence: SEQ ID No.1
[0120] hPDE6B nucleotide sequence: SEQ ID No.2
[0121] EF1α nucleic acid sequence: SEQ ID No.3
[0122] CMV nucleic acid sequence: SEQ ID No.4
[0123] WPREm nucleotide sequence: SEQ ID No.5
[0124] SV40 pA nucleotide sequence: SEQ ID No.6 AAV2 / 8L-ITR nucleotide sequence: SEQ ID No.7 AAV2 / 8R-ITR nucleotide sequence: SEQ ID No.8.
Claims
1. A recombinant adeno-associated virus vector expressing human PDE6B gene, characterized in that: The invention contains an expression cassette, which includes a promoter and a human PDE6B gene, wherein the promoter is a pan-promoter EF-1α or CMV.
2. The recombinant adeno-associated virus vector according to claim 1, characterized in that The expression cassette includes a regulatory sequence downstream, and the regulatory sequence includes a mutated woodchuck stomatitis virus post-transcriptional regulatory element WPRE.
3. The recombinant adeno-associated virus vector according to claim 2, characterized in that The polyadenylation sequence is included downstream of the regulatory sequence, and the polyadenylation sequence is included in the SV40 polyA.
4. The recombinant adeno-associated virus vector according to claim 3, characterized in that The recombinant adeno-associated virus vector comprises the following elements in sequence: a 5' terminal inverted repeat sequence, an expression cassette, a regulatory sequence, a polyadenylation sequence, and a 3' terminal inverted repeat sequence.
5. The recombinant adeno-associated virus vector according to claim 4, characterized in that The serotypes of the adeno-associated virus vector include AAV2 / 8.
6. A plasmid combination, characterized in that It comprises the recombinant adeno-associated virus vector as described in any one of claims 1 to 6 and a helper plasmid for virus packaging; the helper plasmid for virus packaging comprises a Rep-Cap plasmid.
7. Host Escherichia coli and HEK293T cells, characterized in that: (I), transfection or transformation of the recombinant adeno-associated virus vector according to any one of claims 1 to 4; or (II), transfection or transformation of the plasmid combination according to claim 6 or 7.
8. The host according to claim 7, characterized in that The host includes but is not limited to prokaryotes or animal cells; the prokaryotes include but are not limited to Escherichia coli; the animal cells include but are not limited to one or more of CHO cells, BHK cells, Sp2 / 0, HEK-293, HEK293T, Hep G2, HELA, CHO-K1, COS-1, COS-7, NIH3T3, A204, A549, D-407, CHO, HCS-2, HT-29, U87, Sf9 or FD-CHOS.
9. A virus particle prepared by any of the following: (i) a recombinant adeno-associated virus vector as described in any one of claims 1 to 4; or (ii) a plasmid combination as described in claim 6; or (iii) a host as described in claim 7 or 8.
10. Use of any of the following in the preparation of vaccines and / or drugs for preventing, improving and / or treating retinitis pigmentosa; (I) The recombinant adeno-associated virus vector according to any one of claims 1 to 4; or (II), the plasmid combination as claimed in claim 6; Or (III), the virus particle as described in claim 9.
